Bruker (BRKR) Set to Post Earnings on Wednesday

Bruker (NASDAQ:BRKR) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.4188 per share and revenue of $865.16 million for the quarter. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same period in the prior year, the firm posted $0.32 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. On average, analysts expect Bruker to post $2.12 EPS for the current fiscal year and $2.40 EPS for the next fiscal year.

Bruker Trading Up 4.3%

Shares of NASDAQ:BRKR opened at $60.74 on Wednesday. Bruker has a 52-week low of $32.37 and a 52-week high of $66.98. The firm has a fifty day moving average of $58.79 and a 200 day moving average of $50.25.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 annualized dividend and a yield of 0.3%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several research analyst reports. Barclays lifted their price target on Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Citigroup decreased their price objective on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. TD Cowen boosted their target price on Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Leerink Partners upped their target price on Bruker from $60.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, Stifel Nicolaus set a $50.00 price target on shares of Bruker in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $59.43.

Insider Activity

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 27.20% of the stock is owned by insiders.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.